Neurocrine Biosciences, Inc.
NBIX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $795 | $688 | $573 | $628 |
| % Growth | 15.6% | 20.1% | -8.8% | – |
| Cost of Goods Sold | $14 | $11 | $9 | $9 |
| Gross Profit | $781 | $676 | $563 | $618 |
| % Margin | 98.2% | 98.4% | 98.4% | 98.5% |
| R&D Expenses | $250 | $244 | $263 | $186 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $292 | $286 | $277 | $288 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $3 |
| Operating Expenses | $542 | $531 | $540 | $476 |
| Operating Income | $239 | $146 | $24 | $142 |
| % Margin | 30.1% | 21.2% | 4.1% | 22.6% |
| Other Income/Exp. Net | $53 | $14 | -$9 | $21 |
| Pre-Tax Income | $292 | $160 | $15 | $163 |
| Tax Expense | $82 | $52 | $7 | $60 |
| Net Income | $210 | $108 | $8 | $103 |
| % Margin | 26.4% | 15.6% | 1.4% | 16.4% |
| EPS | 2.11 | 1.09 | 0.08 | 1.03 |
| % Growth | 93.6% | 1,262.5% | -92.2% | – |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1 |
| Weighted Avg Shares Out | 99 | 99 | 100 | 100 |
| Weighted Avg Shares Out Dil | 103 | 101 | 103 | 103 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22 | $21 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $7 | $8 | $7 |
| EBITDA | $300 | $153 | $31 | $182 |
| % Margin | 37.7% | 22.2% | 5.5% | 28.9% |